Detail akcie SeaStar Medcl Rg online

Business Summary: SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, SeaStar Medical Holding Corp revenues increased from $68K to $814K. Net loss decreased 55% to $9.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects SURGICAL & MEDICAL INSTRUMENTS segment loss decrease of 30% to $9.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$68.52 to -$7.46.